Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 197

Similar articles for PubMed (Select 21609654)

1.

Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.

Hoyle M, Crathorne L, Garside R, Hyde C.

Health Technol Assess. 2011 May;15 Suppl 1:61-7. doi: 10.3310/hta15suppl1/07. Review.

2.

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008079. doi: 10.1002/14651858.CD008079.pub2. Review.

PMID:
23152253
3.

The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.

Main C, Pitt M, Moxham T, Stein K.

Health Technol Assess. 2010 Oct;14(Suppl. 2):27-32. doi: 10.3310/hta14suppl2/04. Review.

4.

Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.

Walker S, Palmer S, Erhorn S, Brent S, Dyker A, Ferrie L, Horsley W, Macfarlane K, White S, Thomas S.

Health Technol Assess. 2009 Jun;13 Suppl 1:35-40. doi: 10.3310/hta13suppl1/06.

5.

Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.

Dretzke J, Barton P, Kaambwa B, Connock M, Uthman O, Bayliss S, Meads C.

Health Technol Assess. 2010 Oct;14(Suppl. 2):19-26. doi: 10.3310/hta14suppl2/03. Review.

6.

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators.

J Clin Oncol. 2010 Apr 1;28(10):1749-55. doi: 10.1200/JCO.2009.25.3187. Epub 2010 Mar 1. Erratum in: J Clin Oncol. 2010 Aug 1;28(22):3670.

7.

Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.

Ward S, Pilgrim H, Hind D.

Health Technol Assess. 2009 Jun;13 Suppl 1:1-6. doi: 10.3310/hta13suppl1/01.

8.

Alemtuzumab for patients with chronic lymphocytic leukaemia.

Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, Engert A.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD008078. doi: 10.1002/14651858.CD008078.pub2. Review.

PMID:
22336834
9.

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.

Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.

Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10. Review.

10.

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

Bagust A, Greenhalgh J, Boland A, Fleeman N, McLeod C, Dickson R, Dundar Y, Proudlove C, Shaw R.

Pharmacoeconomics. 2010;28(6):439-48. doi: 10.2165/11532220-000000000-00000. Review.

PMID:
20465313
11.

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.

Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R.

Clin Cancer Res. 2010 Sep 1;16(17):4331-8. doi: 10.1158/1078-0432.CCR-10-0570. Epub 2010 Jul 2.

12.

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N.

Pharmacoeconomics. 2012 Apr;30(4):257-70. doi: 10.2165/11595920-000000000-00000. Review.

PMID:
22283690
13.

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

Dickson R, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, Hockenhull J, Martin Saborido C, Oyee J, Ramani VS.

Pharmacoeconomics. 2011 Dec;29(12):1051-62. doi: 10.2165/11591600-000000000-00000.

PMID:
21967156
14.

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.

Boland A, Bagust A, Hockenhull J, Davis H, Chu P, Dickson R.

Health Technol Assess. 2009 Sep;13 Suppl 2:41-8. doi: 10.3310/hta13suppl2/06. Review.

15.

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.

Rafia R, Simpson E, Stevenson M, Papaioannou D.

Pharmacoeconomics. 2013 Jun;31(6):471-8. doi: 10.1007/s40273-013-0044-7. Review.

PMID:
23568332
16.

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.

Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A; Hx-CD20-406 Study Investigators.

Blood. 2011 Nov 10;118(19):5126-9. doi: 10.1182/blood-2011-04-348656. Epub 2011 Aug 19.

17.

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.

Health Technol Assess. 2010 Oct;14(Suppl. 2):33-9. doi: 10.3310/hta14suppl2/05. Review.

18.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

19.

Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).

Boyers D, Jia X, Crowther M, Jenkinson D, Fraser C, Mowatt G.

Health Technol Assess. 2011 May;15 Suppl 1:23-32. doi: 10.3310/hta15suppl1/03. Review.

20.

Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.

Nightingale G.

Ann Pharmacother. 2011 Oct;45(10):1248-55. doi: 10.1345/aph.1P780. Epub 2011 Sep 6. Review.

PMID:
21896924
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk